2022 World Conference on Lung Cancer (ePosters)-EP14.05-014. Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

EP14.05-014. Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

Back to course

Pdf Summary

This study examined trends in overall survival (OS) for adults diagnosed with small cell lung cancer (SCLC) in the United States from 2013-2021. The researchers used data from electronic health records (EHR) and analyzed the outcomes of patients receiving first-line (1L) and second-line (2L) treatments. Prior to 2018, platinum-based chemotherapy plus irinotecan/etoposide was the standard of care for 1L treatment. However, four new checkpoint inhibitors (CPIs) have been approved for SCLC since then. The study aimed to determine if outcomes have improved over time as the standard of care and other factors have changed.<br /><br />The analysis included 7,528 patients who met the study criteria. Among those who initiated 1L treatment, the median OS from the start of 1L in 2013-2017 was 10.1 months, while in 2018-2021 it was 9.8 months. However, 18-month OS from 1L increased from 27% in 2013-2017 to 31% in 2018-2021. For patients initiating 2L treatment, the median OS from the start of 2L was 4.8 months in 2013-2017 and 5.9 months in 2018-2021. The 12-, 18-, and 24-month OS from 2L were also higher in 2018-2021 compared to 2013-2021.<br /><br />Overall, the study found that patients diagnosed with SCLC in more recent years had longer survival when receiving 2L treatment compared to those diagnosed in earlier years. However, the median OS from initiation of 1L remained below 12 months and below 6 months from initiation of 2L treatment. The study emphasizes the ongoing need for effective therapies for SCLC.<br /><br />In summary, this study analyzed data from electronic health records to investigate the trends in survival for adults diagnosed with small cell lung cancer in the United States. The findings suggest that there has been a slight improvement in survival rates for both 1L and 2L treatments in more recent years. However, longer-term survival rates remain low, underscoring the need for more effective therapies for this type of cancer.

Asset Subtitle

Paul Cockrum

Meta Tag

Speaker Paul Cockrum

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

overall survival

small cell lung cancer

SCLC

United States

2013-2021

electronic health records

first-line treatment

second-line treatment

checkpoint inhibitors

improved outcomes